107 related articles for article (PubMed ID: 21215610)
41. Mechanisms of immune dysfunction in renal cell carcinoma.
Derweesh IH; Tannenbaum CS; Rayman PA; Finke JH
Cancer Treat Res; 2003; 116():29-51. PubMed ID: 14650824
[No Abstract] [Full Text] [Related]
42. Novel immunological pathways to the treatment of infections.
Drews J
Infection; 1994; 22(3):157-9. PubMed ID: 7927809
[No Abstract] [Full Text] [Related]
43. Targeting immune modulatory pathways in cancer.
Beckhove P
Clin Immunol; 2018 Jan; 186():32-33. PubMed ID: 28919519
[No Abstract] [Full Text] [Related]
44. Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Chuang HY; Chang YF; Liu RS; Hwang JJ
PLoS One; 2014; 9(10):e109992. PubMed ID: 25333973
[TBL] [Abstract][Full Text] [Related]
45. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
46. Integrated immunogenomic analysis of single-cell and bulk profiling reveals novel tumor antigens and subtype-specific therapeutic agents in lung adenocarcinoma.
Tian S; Luo M; Liao X; Zhang L; Zhang J; Zhang J; Li Y; Qin J; Luan X; Zhang W
Comput Struct Biotechnol J; 2024 Dec; 23():1897-1911. PubMed ID: 38721587
[TBL] [Abstract][Full Text] [Related]
47. CAR-NK cells in combination therapy against cancer: A potential paradigm.
Li J; Hu H; Lian K; Zhang D; Hu P; He Z; Zhang Z; Wang Y
Heliyon; 2024 Mar; 10(5):e27196. PubMed ID: 38486782
[TBL] [Abstract][Full Text] [Related]
48. Contribution of immune cells to bone metastasis pathogenesis.
He N; Jiang J
Front Endocrinol (Lausanne); 2022; 13():1019864. PubMed ID: 36246916
[TBL] [Abstract][Full Text] [Related]
49. The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach.
Hosseinzadeh F; Ai J; Hajifathali A; Muhammadnejad S; Ebrahimi-Barough S; Seyhoun I; Komeili Movahed T; Shirian S; Hosseinzadeh F; Ahmadpour S; Alijani M; Verdi J
Pharmacol Rep; 2022 Apr; 74(2):379-391. PubMed ID: 35089543
[TBL] [Abstract][Full Text] [Related]
50. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma.
Sellers CM; Uhlig J; Ludwig JM; Pollak JS; Taddei TH; Stein SM; Lim JK; Kim HS
Cancer Med; 2021 Aug; 10(16):5395-5404. PubMed ID: 34318618
[TBL] [Abstract][Full Text] [Related]
51. Tyrosine Kinase Inhibitor Cabozantinib Inhibits Murine Renal Cancer by Activating Innate and Adaptive Immunity.
Liu H; Sun S; Wang G; Lu M; Zhang X; Wei X; Gao X; Huang C; Li Z; Zheng J; Zhang Q
Front Oncol; 2021; 11():663517. PubMed ID: 33954115
[TBL] [Abstract][Full Text] [Related]
52. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Bourhis M; Palle J; Galy-Fauroux I; Terme M
Front Immunol; 2021; 12():616837. PubMed ID: 33854498
[TBL] [Abstract][Full Text] [Related]
53. The Binary Classification of Protein Kinases.
Elkoshi Z
J Inflamm Res; 2021; 14():929-947. PubMed ID: 33776467
[TBL] [Abstract][Full Text] [Related]
54. RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?
Chen W; Pan X; Cui X
Front Oncol; 2020; 10():573690. PubMed ID: 33117708
[TBL] [Abstract][Full Text] [Related]
55. Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality.
Zhou X; Hou W; Gao L; Shui L; Yi C; Zhu H
Front Oncol; 2020; 10():1321. PubMed ID: 32850419
[TBL] [Abstract][Full Text] [Related]
56. Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
Mennitto A; Huber V; Ratta R; Sepe P; de Braud F; Procopio G; Guadalupi V; Claps M; Stellato M; Daveri E; Rivoltini L; Verzoni E
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32231117
[TBL] [Abstract][Full Text] [Related]
57. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models.
Zhou Y; Fu C; Kong Y; Pan D; Wang Y; Huang S; Li Z; Ning Z; Lu X; Shan S; Xin L
Anticancer Drugs; 2019 Oct; 30(9):909-916. PubMed ID: 30998512
[TBL] [Abstract][Full Text] [Related]
58. The Contribution of the Immune System in Bone Metastasis Pathogenesis.
Xiang L; Gilkes DM
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823602
[TBL] [Abstract][Full Text] [Related]
59. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
[TBL] [Abstract][Full Text] [Related]
60. Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
Brodaczewska KK; Szczylik C; Kieda C
Contemp Oncol (Pozn); 2018 Mar; 22(1A):14-22. PubMed ID: 29628789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
